Rezolute, Inc. Common Stock (NV) earnings per share and revenue
On Nov 06, 2025, RZLT reported earnings of -0.18 USD per share (EPS) for Q1 26, beating the estimate of -0.27 USD, resulting in a 33.41% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +12.08% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 12 analysts forecast an EPS of -0.19 USD, with revenue projected to reach -- USD, implying an increase of 5.56% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were Rezolute, Inc. Common Stock (NV)'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Rezolute, Inc. Common Stock (NV) reported EPS of -$0.18, beating estimates by 33.41%, and revenue of $0.00, 0% as expectations.
How did the market react to Rezolute, Inc. Common Stock (NV)'s Q1 2026 earnings?
The stock price moved up 12.08%, changed from $9.60 before the earnings release to $10.76 the day after.
When is Rezolute, Inc. Common Stock (NV) expected to report next?
The next earning report is scheduled for Feb 10, 2026.
What are the forecasts for Rezolute, Inc. Common Stock (NV)'s next earnings report?
Based on 12
analysts, Rezolute, Inc. Common Stock (NV) is expected to report EPS of -$0.19 and revenue of -- for Q2 2026.